Celgene International Sàrl (NASDAQ:CELG) announced that data
evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone
in patients with high-risk smoldering multiple myeloma were presented
during the American Society of Hematology’s annual meeting in New
Orleans, LA. The landmark study demonstrated REVLIMID and dexamethasone
prolonged time to progression, including complete responses, with
manageable toxicity.
The multicentre, randomised, open-label study evaluated whether early
treatment with REVLIMID and dexamethasone prolongs time to progression
compared to the observation arm without treatment of high-risk
smoldering multiple myeloma patients.
Patients were treated with REVLIMID and dexamethasone for nine four-week
cycles and then continued treatment with a lower dose of REVLIMID to
sustain disease control until progression. The results showed an overall
response rate of 81%, including 30% with a very good partial response or
better. For the patients who completed the initial nine treatment
cycles, the overall response rate was 91%.